5:48 PM
 | 
Oct 22, 2013
 |  BC Extra  |  Company News

Medivir shares slump after simeprevir briefing documents

Medivir AB (SSE:MVIR B) fell SEK11 (10%) to SEK99.25 on Tuesday after FDA reviewers said simeprevir is generally safe and effective for HCV genotype 1, but that "alternative treatment options should be considered" for genotype 1a patients with the Q80K polymorphism...

Read the full 188 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >